OTCQB: CYTR
CORPORATE OVERVIEW August 2022
CytRx Safe Harbor Statement
THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. SUCH STATEMENTS MAY BE PRECEDED BY THE WORDS "INTENDS," "MAY," "WILL," "PLANS," "EXPECTS," "ANTICIPATES," "PROJECTS," "PREDICTS," ESTIMATES," "AIMS," "BELIEVES," "HOPES," "POTENTIAL" OR SIMILAR WORDS. FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF MANAGEMENT AS WELL AS
CERTAIN ASSUMPTIONS MADE BY AND INFORMATION CURRENTLY AVAIALABLE TO MANAGEMENT, ARE NOT GUARANTEES OF FUTURE PERFORMANCE, AND ARE SUBJECT TO VARIOUS KNOWN AND UNKNOWN RISKS AND
UNCERTAINTIES, MANY OF WHICH ARE BEYOND CYTRX'S CONTROL, AND CANNOT BE PREDICTED OR QUANTIFIED AND
CONSEQUENTLY, RESULTS MAY DIFFER MATERIALLY FROM THOSE EXPRESSED OR IMPLIED BY SUCH FORWARD- LOOKING STATEMENTS AS A RESULT OF VARIOUS RISKS AND UNCERTAINTIES, INCLUDING THOSE RISK FACTORS DISCUSSED IN THE ANNUAL AND QUARTERLY REPORTS THAT CYTRX FILES WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION. STATEMENTS CONTAINED HEREIN ARE MADE AS OF THE DATE OF THIS PRESENTATION UNLESS STATED OTHERWISE, AND NEITHER THIS PRESENTATION, NOR ANY SALE OF SECURITIES, SHALL UNDER ANY CIRCUMSTANCES CREATE AN IMPLICATION THAT THE INFORMATION CONTAINED HEREIN IS CORRECT AS OF ANY TIME AFTER SUCH DATE OR THAT INFORMATION WILL BE UPDATED OR REVISED TO REFLECT INFORMATION THAT SUBSEQUENTLY BECOMES AVAILABLE OR CHANGES OCCURRING AFTER THE DATE HEREOF. CYTRX RESERVES THE RIGHT TO UPDATE, AMEND OR SUPPLEMENT THE INFORMATION AT ANY TIME IN ITS ABSOLUTE DISCRETION (WITHOUT INCURRING ANY OBLIGATION TO DO SO). INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THESE DOCUMENTS FREE OF CHARGE ON THE SEC'S WEB SITE AT WWW.SEC.GOV. CYTRX ASSUMES NO OBLIGATION TO PUBLICLY UPDATE OR REVISE ITS FORWARD-LOOKING STATEMENTS AS A RESULT OF NEW INFORMATION, FUTURE EVENTS OR OTHERWISE.
2
Management and Board
Stephen Snowdy, PhD | Gilad Gordon, MD | John Caloz | |||||
CEO | R&D/Regulatory | CFO | |||||
• | Recently joined CytRx | Consultant | • | 30+ years of CFO | |||
• | PhD Neurobiology | • | Oncology development | experience in life | |||
University of North | expert | sciences sector | |||||
Carolina | • | 30 years experience | • | Occulogix, IRIS Int'l, | |||
• | 20 years of experience | developing cancer | Synarc, Phoenix Int'l | ||||
in medical executive | treatments | Life Sciences | |||||
management | • | Directly responsible | for | ||||
• | Venture capital | 50 INDs, hundreds | of | ||||
• | Medical devices | clinical trials |
- Pharma
- IPO
- Public company management
Board of Directors
- Jennifer Simpson, PhD
Chair of the Board. CEO of Panbela
Therapeutics. Former CEO of Delcath,
Oncology Lead at Imclone, Product
Director Oncology Marketing at Ortho
Biotech
- Joel Caldwell
Chair of Audit Committee. 30 years of experience in tax, finance, and auditing.
- Cary J. Claiborne
Chair of the Compensation Committee.
CEO of Adial Pharmaceuticals Inc.
Former CEO of Prosperity Capital
Management, LLC.
3
Investment Highlights
CytRx has developed elegant tumor targeting and | ||||
release molecules called LADR that are based on | CytRx is stage-diversified, with LADR-based drugs stretching | |||
small molecular entities (no complex antibodies or | from registrational Phase 2 in pancreatic cancer to late pre- | |||
nanoparticles) allowing for higher dosing and | clinical next-gen drugs | |||
lower off-target tox | ||||
- First LADR drug Aldoxorubicin has been licensed to Immunity Bio for $343+ million in milestones and royalties, contingent on regulatory approvals and commercial milestones
- Next-genLADR-based drugs are nearing readiness for IND
- Small and virtual to minimize cash use
- Strong, broad, and global patent portfolio
- Potential short-term upside with licensed product Arimoclomol expected to go to FDA for NDA in 1Q2023 (licensed by KemPharm)
4
LADR=Linker Activated Drug Release
LADR-based drugs take advantage of circulating albumin as Trojan Horse:
- Major source of amino acids for tumors*
- Tumors use as carrier for metabolites, hormones, nutrients*
- Undergoes macropinocytosis*
- Accumulates in tumors due to EPR*
- Long half life*
LADR:
Ultra High Potency Drug
Payload
- Payloads are effective in the nanomolar range
- Similar to those used for approved ADCs (auristatins and maytansinoids)
Cleavable Linker
- Novel linker keeps the highly potent drug payload inactive until the conjugate reaches the tumor
- The linker is then cleaved when exposed to lower pH in tumor and intracellular environments
Targeting
- Ensures rapid and selective binding to circulating serum albumin
- Serum albumin transports the LADR™ drug to the tumor
* Kratz, F. Albumin as a drug carrier. J Cont Rel (2008) 132:171-183
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
CytRx Corporation published this content on 10 September 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 September 2022 23:09:03 UTC.